This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Q2 Earnings Beat on Strong Individual MA Unit
by Zacks Equity Research
Humana's (HUM) Q2 results gain from strong pharmacy revenues and revenue growth within the Insurance segment, partly offset by higher benefits expenses.
Centene (CNC) Q2 Earnings Beat Estimates on Membership Growth
by Zacks Equity Research
Centene's (CNC) Q2 results benefit from growing premium and service revenues coupled with improving membership.
Compared to Estimates, Centene (CNC) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Centene (CNC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Centene (CNC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 2.44% and 3.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Centene (CNC)
by Zacks Equity Research
Centene (CNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Humana (HUM) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Growing Customer Base Aid Centene (CNC) in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) Q2 results are likely to reflect growing Medicaid and Marketplace membership, coupled with an improved HBR, partly offset by escalating medical expenses.
Centene (CNC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Centene (CNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will High Tech Costs Hurt Teladoc Health (TDOC) in Q2 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) Q2 results are likely to have benefited from improved access fees and growing BetterHelp membership, partly offset by elevated technology and development expenses.
Why Centene (CNC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UnitedHealth Group (UNH) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 3.72% and 2.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Centene (CNC) Stock for Now
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and the streamlining of businesses poise Centene (CNC) well for growth.
Here's Why Centene (CNC) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
U.S. Health Insurers Are Tumbling: Should You be Worried?
by Kaibalya Pravo Dey
Demand for procedures like hip and knee surgeries is rising, which will leave fewer premiums in hand after paying for the procedures for the health insurers.
UnitedHealth (UNH) Falls 6.4% on Cost Woes of Resumed Surgeries
by Zacks Equity Research
UnitedHealth's (UNH) Optum Health unit is likely to witness higher utilization, especially in ambulatory surgery operations.
Centene (CNC) Divests Apixio to Boost Its Core Business
by Zacks Equity Research
Centene (CNC) completes the sale of Apixio to New Mountain Capital in a bid to dispose of non-core assets and grow its core Managed Care business.
Humana (HUM) Wins Contract to Serve Oklahoma's Medicaid Members
by Zacks Equity Research
Humana (HUM) secures a contract from the OHCA and is likely to provide improved health outcomes for Medicaid members of Oklahoma.
Centene (CNC) to Provide Managed Care for SoonerSelect Program
by Zacks Equity Research
Centene (CNC) wins managed care contract to serve people in Oklahoma through the SoonerSelect and SoonerSelect Children's Specialty Plan programs.
Here's Why Centene (CNC) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Industry Outlook Highlights UnitedHealth Group, The Cigna Group, Humana, Centene Corporation and Molina Healthcare
by Zacks Equity Research
UnitedHealth Group, The Cigna Group, Humana, Centene Corporation and Molina Healthcare are part of the Zacks Industry Outlook article.
5 HMO Industry Stocks to Watch as Technology Expenses Take a Toll
by Debasmita Chatterjee
The Medical-HMO industry is witnessing growth in customer base and an active M&A strategy. However, high technology expenses and medical personnel shortage raise concerns. UNH, CI, HUM, CNC and MOH are likely to navigate the industry storms.
Centene (CNC) Down 3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights PepsiCo, Salesforce, Advanced Micro Devices, Centene and Gartner
by Zacks Equity Research
PepsiCo, Salesforce, Advanced Micro Devices, Centene and Gartner are part of the Zacks top Analyst Blog.
Top Analyst Reports for PepsiCo, Salesforce & AMD
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), Salesforce, Inc. (CRM) and Advanced Micro Devices, Inc. (AMD).
Here's Why Hold Strategy is Apt for Centene (CNC) Stock Now
by Zacks Equity Research
Centene's (CNC) health benefit ratio is estimated at 87.1-87.7% for 2023, signaling better operating efficiency.